---
title: "Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294061137.md"
description: "Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company (Nasdaq: PVLA), will release its second quarter 2026 financial report on August 4, 2026, before the market opens. The company, based in Wayne, Pa., focuses on developing therapies for rare skin diseases and vascular malformations lacking FDA-approved treatments. Palvella will host an investor conference call at 8:30 a.m. ET on the same day to review the results and offer a corporate update."
datetime: "2026-07-28T11:33:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294061137.md)
  - [en](https://longbridge.com/en/news/294061137.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294061137.md)
generator: "portal-rs"
---

# Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company (Nasdaq: PVLA), will release its second quarter 2026 financial report on August 4, 2026, before the market opens. The company, based in Wayne, Pa., focuses on developing therapies for rare skin diseases and vascular malformations lacking FDA-approved treatments. Palvella will host an investor conference call at 8:30 a.m. ET on the same day to review the results and offer a corporate update.

### Related Stocks

- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

- [PVLA: Advanced NDA submission and clinical pipeline with $250.6M cash; net loss widened to $21.9M](https://longbridge.com/en/news/294821621.md)
- [Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands](https://longbridge.com/en/news/296027938.md)
- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)
- [Syn updates 2026 financial calendar for interim results release](https://longbridge.com/en/news/296331010.md)
- [09:02 ETEvolved By Nature's Peptide Platform Used in FDA-Cleared Prescription Therapy for the Management of Atopic Dermatitis](https://longbridge.com/en/news/296496101.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**